BioSpace News Archive

NRx Pharmaceuticals (Nasdaq: NRXP ), today announced that a revised Investigational New Drug module on the manufacturing of ZYESAMI™ (aviptadil) was submitted to the US Food and Drug Administration (FDA)

Hansoh Pharmaceutical Group Co, Ltd (SEHK: 3692), a leading R&D driven biopharmaceutical company in China and OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a licensing and collaboration agreement to discover, develop and commercialize siRNA therapeutics in key targeted indications in Greater China, which includes mainland China, Taiwan, Hong Kong and Macau.

Signature Biologics, LLC., today announced they have joined the ranks of the Rare Disease Company Coalition.

Poseida Therapeutics, Inc. (Nasdaq: PSTX), today announced that it has entered into a research collaboration and exclusive license agreement with Takeda Pharmaceutical Company Limited (“Takeda”).

Sutro Biopharma, Inc. and BioNova Pharmaceuticals Limited today jointly announced an option agreement for BioNova to develop and commercialize STRO-001, a CD74-targeting Antibody-Drug Conjugate (ADC), for patients with hematologic cancers, in Greater China, including mainland China, Hong Kong, Macau and Taiwan.

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) (“Protagonist” or “the Company”) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer and Scott Plevy , M.D., Executive Vice President and Therapeutic Head, Gastroenterology will participate in a fireside chat at the upcoming Jefferies Next Generation IB Therapeutics Summit taking place virtually on October 19, 2021.

4D pharma plc today announces that 4D management will present at the Jefferies Virtual Next Generation IBD Therapeutics Summit being held on October 19, 2021.

AavantiBio today announced it is partnering with the University of Florida to research and develop next generation gene therapy capsids with the goal of creating safer, more effective, and tissue specific gene therapies.

LianBio today announced the appointment of Susan Silbermann to the company’s Board of Directors.

Radicle Science secured its initial seed funding in Q4 2020 and surpassed numerous major milestones with accelerating momentum in the first three quarters of 2021.